Commentary · 21 Feb 2026
Conference abstractPublished 21 Oct 2013
Synthesis and anticancer screening studies of benzhydrylpand#305;perazand#305;ne derivatives
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This lecture will cover our study on benzhydrylpiperazine derivatives and their cytotoxic activities. Our group prepared fifty one compounds with carboxamide, carbothioamide, benzoyl and sulfonyl moieties. Benzhydrylpiperazine, 4-chlorobenzhydrylpiperazine and 4,4?-difluorobenzhydrylpiperazine were synthesized by reflux of piperazine and suitable benzhydryl chlorides in alkali medium. Target compounds were synthesized with reactions of benzhydrylpiperazine derivatives with suitable isocyanates, isothiocyanates, benzoyl chlorides and sulfonyl chlorides in room temperature with triethylamine. Structures of compounds were clarified with IR, 1H-NMR, 13 C-NMR, mass spectroscopies and elemental analyses. In vitro cytotoxic activities were screened in comparison with camptothecin (positive control) and 5-fluorouracil (reference) by sulphorhodamine B assay against breast cancer (MCF-7), hepatocellular carcinoma (HUH-7) and colorectal carcinoma (HCT-116) cell lines. Against HUH-7 cell line, in general, 4-chlorobenzhydrylpiperazine derivatives were more potent than other derivatives. The most potent compound against this cell line was N-(4-cyanophenyl)-4-[(4-chlorophenyl)(phenyl) methyl]piperazine-1-carboxamide (compound 25; IC 50 =1.29 μM). The most potent compound against MCF-7 cell line was 1-(4-bromobenzoyl)-4-[bis(4-fluorophenyl)methyl]piperazine HCl (compound 36; IC 50 = 2.21 μM). The most potent compounds against HCT-116 cell line were N-tert-butyl-4-(diphenylmethyl)piperazine-1-carboxamide (compound 2; IC 50 =1.01 μM) and N-(4-cyanophenyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-carboxamide (compound 25; IC 50 =1.81 μM).
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “E. Ece Gurdal”
- BylineArticles whose byline prints “Mine Yarim”
- BylineArticles whose byline prints “Irem Durmaz”
- BylineArticles whose byline prints “Rengul Cetin-Atalay”
